WO2025061684 - MULTISPECIFIC ANTIBODIES FOR NEUROLOGICAL DISORDERS
National phase entry is expected:
Publication Number
WO/2025/061684
Publication Date
27.03.2025
International Application No.
PCT/EP2024/075934
International Filing Date
17.09.2024
Title **
[English]
MULTISPECIFIC ANTIBODIES FOR NEUROLOGICAL DISORDERS
[French]
ANTICORPS MULTISPÉCIFIQUES POUR TROUBLES NEUROLOGIQUES
Applicants **
KATHOLIEKE UNIVERSITEIT LEUVEN
VIB VZW
Inventors
CUYPERS, Marie-Lynn
DE STROOPER, Bart
DEWILDE, Maarten
JASPERS, Tom
Priority Data
23198043.4
18.09.2023
EP
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2335 | |
| EPO | Filing, Examination, Granting | 11713 | |
| Japan | Filing, Examination, Granting | 2338 | |
| South Korea | Filing, Examination, Granting | 2448 | |
| USA | Filing, Examination, Granting | 6140 |
Total:
24,974
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The invention relates to multispecific polypeptides comprising a first protein for the prevention, treatment or detection of a neurological disorder in the central nervous system, a second protein binding specifically to a protein expressed on the blood brain barrier, wherein the protein expressed on the brain blood barrier mediates enhanced uptake of compounds over the BBB, and a third protein binding specifically to a protein in the CNS.[French]
L'invention concerne des polypeptides multispécifiques comprenant une première protéine pour la prévention, le traitement ou la détection d'un trouble neurologique dans le système nerveux central, une deuxième protéine se liant spécifiquement à une protéine exprimée sur la barrière hémato-encéphalique, la protéine exprimée sur la barrière hémato-encéphalique médiant l'absorption améliorée de composés sur la BHE, et une troisième protéine se liant spécifiquement à une protéine dans le SNC.